The World Health Organization (WHO) recognizes antimicrobial resistance (AMR) as one of the paramount public health threats of the 21st century. Notably, this issue is exacerbated in low- and middle-income countries (LMICs) where AMR-related bacterial infections are estimated to contribute significantly to mortality, causing approximately 5 million deaths globally annually, with 4.3 million of these occurring in LMICs. The challenges in these regions, including a high burden of infectious diseases and limited health system resources, facilitate the rise of inappropriate antimicrobial use and resistance development.
The Lao AntiMicrobial Prescribing Application (LAMPA) trial provides insights into the relationship between access to prescribing guidelines and adherence in LMICs. Conducted over two years, this stepped-wedge cluster randomized controlled trial involved six hospitals in Laos. Initially, hospitals received a paper-based version of the national prescribing guidelines and an introductory session. Subsequently, the intervention—a smartphone application containing the same guidelines—was rolled out to select hospitals along with a single training session on antimicrobial stewardship.
The primary outcome assessed was the proportion of antimicrobial prescriptions aligned with established guidelines, using regular point prevalence surveys for evaluation. Results indicated guideline adherence was 17.0% in the reference group and improved to 25.6% in the intervention group. However, the intervention's impact was not statistically significant, which suggests that merely providing access to guidelines via a smartphone application does not lead to improved adherence.
The findings from the LAMPA trial indicate that the approach of enhancing guideline access through technology in LMICs is not sufficient. While the study successfully demonstrated feasibility in implementing a smartphone-based guidance tool, the marginal increase in guideline adherence underscores the complexities of prescriber behavior. Educators and policymakers should recognize that improving access alone does not translate to better adherence, hinting at the necessity for more engaging and continuous educational strategies tailored to prescriber needs and behaviors.
A significant observation from discussions with prescribers involved in the trial is their reliance on established clinical practices over newly introduced guidelines. Many prescribers perceived the smartphone app as an additional, if not unnecessary, resource, accessing it infrequently, approximately once a month. Their established routines and clinical experiences dictated prescribing choices, placing less weight on formal guidelines.
Multiple factors contributing to the low adherence rates observed in the trial stem from health system constraints. Particularly in many LMICs, diagnostic microbiology access is limited, leading to a predominance of empirical antibiotic prescriptions. In such an environment, attempts to tailor therapy based on culture results remain rare, complicating efforts to ensure guideline-concordant care.
Moreover, a structural deficiency in the healthcare workforce and auxiliary resources can inhibit the development of robust antimicrobial stewardship programs. Many clinicians in LMICs encounter barriers such as insufficient training or familiarity with electronic tools, leading to skepticism regarding the value these resources may provide.
The quality of medications available in these regions is another compounding issue. Substandard or falsified medications contribute to decreased confidence in treatment protocols, impacting prescriber choices and adherence.
To establish effective antimicrobial stewardship, approaches must be comprehensive and multifaceted. Educational efforts should not only provide access to guidelines but also actively engage clinicians through ongoing training and reinforcement of best practices. Furthermore, addressing the systemic issues that underpin antibiotic prescribing behaviors—including improving laboratory capacities, diagnostic access, and combating substandard medications—will be paramount in developing and executing effective stewardship initiatives in LMICs.
In conclusion, the LAMPA trial illustrates that while technology can improve access to antimicrobial prescribing guidelines, it alone cannot enhance adherence. Future efforts must combine guideline distribution with interactive and educational strategies tailored to the unique challenges in low- and middle-income countries. This holistic approach could play a crucial role in combating the increasing tide of AMR and ensuring effective use of antimicrobial agents in these regions.